Availability and affordability of anticancer medicines at cancer treating hospitals in Rwanda.
Affordability
Anti-cancer medicines
Availability
Cancer treating hospitals
Rwanda
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
30 Jun 2023
30 Jun 2023
Historique:
received:
04
11
2022
accepted:
15
06
2023
medline:
3
7
2023
pubmed:
1
7
2023
entrez:
30
6
2023
Statut:
epublish
Résumé
Availability and accessibility of anti-cancer medicines is the pillar of cancer management, and it is one of the main concerns in low-income countries including Rwanda. The objective of this study was to assess the availability and affordability of anticancer medicines at cancer-treating hospitals in Rwanda. A descriptive cross-sectional study was conducted at 5 cancer-treating hospitals in Rwanda. Quantitative data were collected from stock cards and software that manage medicines and included the availability of anti-cancer medicines at the time of data collection, their stock status within the last two years, and the selling price. The study found the availability of anti-cancer medicines at 41% in public hospitals at the time of data collection, and 45% within the last two years. We found the availability of anti-cancer medicines at 45% in private hospitals at the time of data collection, and 61% within the last two years. 80% of anti-cancer medicines in private hospitals were unaffordable while 20% were affordable. The public hospital that had most of the anti-cancer medicines in the public sector provided free services to the patients, and no cost was applied to the anti-cancer medicines. The availability of anti-cancer medicines in cancer-treating hospitals is low in Rwanda, and most of them are unaffordable. There is a need to design strategies that can increase the availability and affordability of anti-cancer medicines, for the patients to get recommended cancer treatment options.
Sections du résumé
BACKGROUND
BACKGROUND
Availability and accessibility of anti-cancer medicines is the pillar of cancer management, and it is one of the main concerns in low-income countries including Rwanda. The objective of this study was to assess the availability and affordability of anticancer medicines at cancer-treating hospitals in Rwanda.
METHODOLOGY
METHODS
A descriptive cross-sectional study was conducted at 5 cancer-treating hospitals in Rwanda. Quantitative data were collected from stock cards and software that manage medicines and included the availability of anti-cancer medicines at the time of data collection, their stock status within the last two years, and the selling price.
RESULTS
RESULTS
The study found the availability of anti-cancer medicines at 41% in public hospitals at the time of data collection, and 45% within the last two years. We found the availability of anti-cancer medicines at 45% in private hospitals at the time of data collection, and 61% within the last two years. 80% of anti-cancer medicines in private hospitals were unaffordable while 20% were affordable. The public hospital that had most of the anti-cancer medicines in the public sector provided free services to the patients, and no cost was applied to the anti-cancer medicines.
CONCLUSION
CONCLUSIONS
The availability of anti-cancer medicines in cancer-treating hospitals is low in Rwanda, and most of them are unaffordable. There is a need to design strategies that can increase the availability and affordability of anti-cancer medicines, for the patients to get recommended cancer treatment options.
Identifiants
pubmed: 37391753
doi: 10.1186/s12913-023-09706-y
pii: 10.1186/s12913-023-09706-y
pmc: PMC10314384
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
717Informations de copyright
© 2023. The Author(s).
Références
Ann Glob Health. 2020 Sep 25;86(1):123
pubmed: 33024709
J Natl Cancer Inst. 2016 Oct 20;109(2):
pubmed: 27754926
J Oncol Pharm Pract. 2023 Jun;29(4):956-957
pubmed: 36734132
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Rural Remote Health. 2023 Jan;23(1):8174
pubmed: 36802702
PLOS Glob Public Health. 2023 Feb 27;3(2):e0001534
pubmed: 36963043
BMC Pharmacol Toxicol. 2015 Dec 23;16:43
pubmed: 26699711
Risk Manag Healthc Policy. 2022 Dec 29;15:2421-2433
pubmed: 36601534
Front Public Health. 2021 Apr 30;9:628744
pubmed: 33996712
Nat Rev Cancer. 2014 Dec;14(12):815-21
pubmed: 25355378
East Afr J Public Health. 2011 Mar;8(1):52-7
pubmed: 22066285
Lancet Glob Health. 2022 Dec;10(12):e1860-e1866
pubmed: 36183737
Oncotarget. 2017 May 9;8(42):71548-71555
pubmed: 29069727
Health Aff (Millwood). 2016 Jan;35(1):54-61
pubmed: 26733701
JCO Glob Oncol. 2020 Jul;6:1171-1177
pubmed: 32701365
PLoS One. 2020 Aug 3;15(8):e0236411
pubmed: 32745100
Nat Rev Clin Oncol. 2023 Jan;20(1):7-15
pubmed: 36380066
Oncologist. 2022 Nov 3;27(11):958-970
pubmed: 36094141
Public Health Action. 2021 Mar 21;11(1):5-11
pubmed: 33777715
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Glob Health. 2021 Apr 17;11:03067
pubmed: 33884189
Trop Med Int Health. 2021 Aug;26(8):953-961
pubmed: 33892521
BMC Health Serv Res. 2020 May 14;20(1):424
pubmed: 32410676
JCO Glob Oncol. 2022 May;8:e2100395
pubmed: 35623016
BMC Cancer. 2018 Jan 3;18(1):14
pubmed: 29298681